454 related articles for article (PubMed ID: 22006858)
1. Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO⁻₃ output.
Baghdasaryan A; Claudel T; Gumhold J; Silbert D; Adorini L; Roda A; Vecchiotti S; Gonzalez FJ; Schoonjans K; Strazzabosco M; Fickert P; Trauner M
Hepatology; 2011 Oct; 54(4):1303-12. PubMed ID: 22006858
[TBL] [Abstract][Full Text] [Related]
2. Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR.
Jadhav K; Xu Y; Xu Y; Li Y; Xu J; Zhu Y; Adorini L; Lee YK; Kasumov T; Yin L; Zhang Y
Mol Metab; 2018 Mar; 9():131-140. PubMed ID: 29361497
[TBL] [Abstract][Full Text] [Related]
3. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism.
Pathak P; Liu H; Boehme S; Xie C; Krausz KW; Gonzalez F; Chiang JYL
J Biol Chem; 2017 Jun; 292(26):11055-11069. PubMed ID: 28478385
[TBL] [Abstract][Full Text] [Related]
4. Long-term Administration of Nuclear Bile Acid Receptor FXR Agonist Prevents Spontaneous Hepatocarcinogenesis in Abcb4
Cariello M; Peres C; Zerlotin R; Porru E; Sabbà C; Roda A; Moschetta A
Sci Rep; 2017 Sep; 7(1):11203. PubMed ID: 28894223
[TBL] [Abstract][Full Text] [Related]
5. FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity.
Wang XX; Wang D; Luo Y; Myakala K; Dobrinskikh E; Rosenberg AZ; Levi J; Kopp JB; Field A; Hill A; Lucia S; Qiu L; Jiang T; Peng Y; Orlicky D; Garcia G; Herman-Edelstein M; D'Agati V; Henriksen K; Adorini L; Pruzanski M; Xie C; Krausz KW; Gonzalez FJ; Ranjit S; Dvornikov A; Gratton E; Levi M
J Am Soc Nephrol; 2018 Jan; 29(1):118-137. PubMed ID: 29089371
[TBL] [Abstract][Full Text] [Related]
6. The role of FXR and TGR5 in reversing and preventing progression of Western diet-induced hepatic steatosis, inflammation, and fibrosis in mice.
Wang XX; Xie C; Libby AE; Ranjit S; Levi J; Myakala K; Bhasin K; Jones BA; Orlicky DJ; Takahashi S; Dvornikov A; Kleiner DE; Hewitt SM; Adorini L; Kopp JB; Krausz KW; Rosenberg A; McManaman JL; Robertson CE; Ir D; Frank DN; Luo Y; Gonzalez FJ; Gratton E; Levi M
J Biol Chem; 2022 Nov; 298(11):102530. PubMed ID: 36209823
[TBL] [Abstract][Full Text] [Related]
7. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist.
Rizzo G; Passeri D; De Franco F; Ciaccioli G; Donadio L; Rizzo G; Orlandi S; Sadeghpour B; Wang XX; Jiang T; Levi M; Pruzanski M; Adorini L
Mol Pharmacol; 2010 Oct; 78(4):617-30. PubMed ID: 20631053
[TBL] [Abstract][Full Text] [Related]
8. Probiotic Lactobacillus rhamnosus GG Prevents Liver Fibrosis Through Inhibiting Hepatic Bile Acid Synthesis and Enhancing Bile Acid Excretion in Mice.
Liu Y; Chen K; Li F; Gu Z; Liu Q; He L; Shao T; Song Q; Zhu F; Zhang L; Jiang M; Zhou Y; Barve S; Zhang X; McClain CJ; Feng W
Hepatology; 2020 Jun; 71(6):2050-2066. PubMed ID: 31571251
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous inhibition of FXR and TGR5 exacerbates atherosclerotic formation.
Miyazaki-Anzai S; Masuda M; Kohno S; Levi M; Shiozaki Y; Keenan AL; Miyazaki M
J Lipid Res; 2018 Sep; 59(9):1709-1713. PubMed ID: 29976576
[TBL] [Abstract][Full Text] [Related]
10. Deficiency of Both Farnesoid X Receptor and Takeda G Protein-Coupled Receptor 5 Exacerbated Liver Fibrosis in Mice.
Ferrell JM; Pathak P; Boehme S; Gilliland T; Chiang JYL
Hepatology; 2019 Sep; 70(3):955-970. PubMed ID: 30664797
[TBL] [Abstract][Full Text] [Related]
11. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism.
Pathak P; Xie C; Nichols RG; Ferrell JM; Boehme S; Krausz KW; Patterson AD; Gonzalez FJ; Chiang JYL
Hepatology; 2018 Oct; 68(4):1574-1588. PubMed ID: 29486523
[TBL] [Abstract][Full Text] [Related]
12. Bile Acid G Protein-Coupled Membrane Receptor TGR5 Modulates Aquaporin 2-Mediated Water Homeostasis.
Li S; Qiu M; Kong Y; Zhao X; Choi HJ; Reich M; Bunkelman BH; Liu Q; Hu S; Han M; Xie H; Rosenberg AZ; Keitel V; Kwon TH; Levi M; Li C; Wang W
J Am Soc Nephrol; 2018 Nov; 29(11):2658-2670. PubMed ID: 30305310
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic activation of hepatic farnesoid X receptor prevents parenteral nutrition-associated cholestasis in mice.
El Kasmi KC; Ghosh S; Anderson AL; Devereaux MW; Balasubramaniyan N; D'Alessandro A; Orlicky DJ; Suchy FJ; Shearn CT; Sokol RJ
Hepatology; 2022 Feb; 75(2):252-265. PubMed ID: 34387888
[TBL] [Abstract][Full Text] [Related]
14. Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the
Fuchs CD; Sroda N; Scharnagl H; Gupta R; Minto W; Stojakovic T; Liles JT; Budas G; Hollenback D; Trauner M
JHEP Rep; 2023 Nov; 5(11):100874. PubMed ID: 37841639
[TBL] [Abstract][Full Text] [Related]
15. Dual Agonist of Farnesoid X Receptor and Takeda G Protein-Coupled Receptor 5 Inhibits Hepatitis B Virus Infection In Vitro and In Vivo.
Ito K; Okumura A; Takeuchi JS; Watashi K; Inoue R; Yamauchi T; Sakamoto K; Yamashita Y; Iguchi Y; Une M; Wakita T; Umezawa K; Yoneda M
Hepatology; 2021 Jul; 74(1):83-98. PubMed ID: 33434356
[TBL] [Abstract][Full Text] [Related]
16. A dual agonist of farnesoid X receptor (FXR) and the G protein-coupled receptor TGR5, INT-767, reverses age-related kidney disease in mice.
Wang XX; Luo Y; Wang D; Adorini L; Pruzanski M; Dobrinskikh E; Levi M
J Biol Chem; 2017 Jul; 292(29):12018-12024. PubMed ID: 28596381
[TBL] [Abstract][Full Text] [Related]
17. INT-767 improves histopathological features in a diet-induced
Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
[TBL] [Abstract][Full Text] [Related]
18. FXR and TGR5 Agonists Ameliorate Liver Injury, Steatosis, and Inflammation After Binge or Prolonged Alcohol Feeding in Mice.
Iracheta-Vellve A; Calenda CD; Petrasek J; Ambade A; Kodys K; Adorini L; Szabo G
Hepatol Commun; 2018 Nov; 2(11):1379-1391. PubMed ID: 30411084
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression.
Erice O; Labiano I; Arbelaiz A; Santos-Laso A; Munoz-Garrido P; Jimenez-Agüero R; Olaizola P; Caro-Maldonado A; Martín-Martín N; Carracedo A; Lozano E; Marin JJ; O'Rourke CJ; Andersen JB; Llop J; Gómez-Vallejo V; Padro D; Martin A; Marzioni M; Adorini L; Trauner M; Bujanda L; Perugorria MJ; Banales JM
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1335-1344. PubMed ID: 28916388
[TBL] [Abstract][Full Text] [Related]
20. Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15.
Zhou M; Luo J; Chen M; Yang H; Learned RM; DePaoli AM; Tian H; Ling L
J Hepatol; 2017 Jun; 66(6):1182-1192. PubMed ID: 28189755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
